Skip to main content
TipRanks
Go Ultimate75% OFF

Hester Biosciences Limited (HESTERBIO) AI Stock Analysis

0 Followers
IN:HESTERBIO

Hester Biosciences Limited

(NSE:HESTERBIO)

Select Model
Rating:74Outperform
Price Target:INR 2,710.00â–²(16.31% Upside)
Action:reiterated
Date:10/14/26

The overall score of 74 is heavily anchored by Hester Biosciences' outstanding financial fundamentals, including strong revenue growth, recovering margins, and robust free cash flow generation. This is further supported by an attractive valuation characterized by a low P/E ratio. The primary factor tempering the score is weak short-term technical momentum, although long-term technical support remains intact.

Positive Factors
Steady Revenue GrowthMulti-year revenue expansion indicates continued demand for Hester Biosciences’ veterinary and poultry healthcare offerings. The 2026 re-acceleration strengthens the company’s growth base and can support operating leverage, reinvestment, and broader market development over the next several quarters.
Negative Factors
Margin VolatilityHistorical margin volatility makes current profitability less dependable as a guide to future earnings. Inconsistent cost structure and gross-margin performance can create uneven results, reduce forecasting confidence, and limit the durability of the latest profitability rebound.

Hester Biosciences Limited (HESTERBIO) vs. iShares MSCI India ETF (INDA)

-40%-20%0%20%40%60%IN:HESTERBIO+38.16%INDA-5.34%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 19.47B
Dividend Yield
0.47%
Average Volume (3M)
301
Price to Earnings (P/E)
13.9
Beta (1Y)
0.58
Revenue Growth
17.48%
EPS Growth
224.08%
Country
India
Employees
483
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - Specialty & Generic

Hester Biosciences Limited Business Overview & Revenue Model

Company Description

Hester Biosciences Limited, founded in 1987 and headquartered in Ahmedabad, India, specializes in the production and commercialization of veterinary vaccines and a comprehensive array of animal health solutions. The company's operations span both dom...

Hester Biosciences Limited Financial Statement Overview

Summary

Hester Biosciences exhibits a highly robust financial profile. The company boasts consistent revenue growth, a dramatic doubling in net income year-over-year, and a sharp recovery in profit margins. Furthermore, the balance sheet is de-leveraging significantly, supported by strong positive free cash flow generation following a period of capital expansion.

Income Statement

84Very Positive

Balance Sheet

88Very Positive

Cash Flow

82Very Positive
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue3.54B3.33B3.11B3.05B2.66B2.35B
Gross Profit2.11B1.69B2.08B972.64M1.89B1.66B
EBITDA1.12B866.58M649.76M582.46M619.20M731.93M
Net Income1.42B556.39M274.88M188.89M266.27M393.20M
Balance Sheet
Total Assets6.83B6.78B6.53B6.62B6.70B5.62B
Cash, Cash Equivalents and Short-Term Investments272.37M65.38M72.19M153.04M148.17M252.20M
Total Debt1.09B1.95B2.13B2.44B2.74B2.28B
Total Liabilities2.08B3.10B3.27B3.59B3.81B2.95B
Stockholders Equity4.68B3.60B3.14B2.92B2.80B2.60B
Cash Flow
Free Cash Flow0417.03M439.20M237.37M-541.66M-869.02M
Operating Cash Flow0595.31M645.11M481.34M235.96M88.08M
Investing Cash Flow0-49.00M-190.03M-226.54M-769.99M-1.17B
Financing Cash Flow0-421.53M-517.17M-260.45M417.58M1.12B

Hester Biosciences Limited Technical Analysis

Technical Analysis SentimentPositive
Last Price2329.90

Price Trends

50DMA2222.08Positive
100DMA2288.64Positive
200DMA1956.77Positive

Market Momentum

MACD38.90Negative
RSI56.01Neutral
STOCH27.30Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:HESTERBIO, the sentiment is Positive. The current price of 2329.90 is above the 20-day moving average (MA) of 2260.03, above the 50-day MA of 2222.08, and above the 200-day MA of 1956.77, indicating a bullish trend. The MACD of 38.90 indicates Negative momentum. The RSI at 56.01 is Neutral, neither overbought nor oversold. The STOCH value of 27.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:HESTERBIO.

Hester Biosciences Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:HESTERBIO against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:HESTERBIOIN:HESTERBIO74OutperformINR 19.82B13.86―0.47%17.48%224.08%
IN:VENUSREMIN:VENUSREM72OutperformINR 20.34B16.75―0.66%20.22%73.03%
IN:GUJTHEMIN:GUJTHEM59NeutralINR 45.40B78.08―0.19%17.51%9.17%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:ZIMLABIN:ZIMLAB53NeutralINR 7.29B256.58――13.14%-60.77%
IN:WANBURYIN:WANBURY48NeutralINR 6.20B11.70――7.45%-6.56%
IN:SIGACHIIN:SIGACHI47NeutralINR 10.93B43.67―0.35%-3.07%―

* General Sector Average

Performance Comparison

0%100%200%IN:HESTERBIOIN:SIGACHIIN:VENUSREMIN:WANBURYIN:ZIMLABIN:GUJTHEMDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:HESTERBIO and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:HESTERBIOHester Biosciences Limited2329.90674.9240.78%
IN:SIGACHISigachi Industries Limited28.61-6.70-18.97%
IN:VENUSREMVenus Remedies Limited1521.50879.63137.04%
IN:WANBURYWanbury Limited177.45-50.75-22.24%
IN:ZIMLABZim Laboratories Ltd.135.8561.6883.16%
IN:GUJTHEMGujarat Themis Biosyn Ltd348.80-87.54-20.06%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 14, 2026